Lipocine to Present at the H.C. Wainwright 4th Annual NASH Investor Conference
Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company, will present an update on its product LPCN 1144 at the virtual H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company, will present an update on its product LPCN 1144 at the virtual H.C. Wainwright 4th Annual NASH Investor Conference on October 5, 2020, from 3:30 PM to 4:00 PM Eastern Time. LPCN 1144, an oral bioidentical testosterone, is being evaluated for treating non-cirrhotic NASH. The presentation will discuss recent clinical findings and future development plans. The company is also advancing other products in its pipeline, including TLANDO and LPCN 1107.
Details
News Market Reaction – LPCN
The recorded move for LPCN in the trading session of this news was -1.43%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SALT LAKE CITY, Sept. 29, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, will provide an update on LPCN 1144, an oral product of bioidentical testosterone being evaluated for the treatment of non-cirrhotic, NASH at the H.C. Wainwright 4th Annual NASH Investor Conference, being held virtually on October 5, 2020.
Presentation Details
Date: Monday, October 5
Time: 3:30pm – 4:00pm Eastern Time
Webcast: https://journey.ct.events/view/edcdaa3d-4910-4583-81d2-9d4c0fe165cd
About Lipocine
Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes TLANDO, LPCN 1144, TLANDO XR, LPCN 1148 and LPCN 1107. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, is designed to help restore normal testosterone levels in hypogonadal men. Lipocine has resubmitted its NDA to the FDA for TLANDO and is awaiting FDA decision on its NDA. LPCN 1144, an oral product of bioidentical testosterone, recently completed a proof-of-concept clinical study demonstrating the potential utility in the treatment of non-cirrhotic NASH. LPCN 1144 is currently being studied in a Phase 2 clinical study. TLANDO XR, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing. In a phase 2 clinical evaluation when administered as once daily or twice daily TLANDO XR met the typical primary and secondary end points. LPCN 1148 is an oral prodrug of bioidentical testosterone targeted for the treatment of cirrhosis. LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate, with end of phase 2 meeting completed, indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA. For more information, please visit www.lipocine.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/lipocine-to-present-at-the-hc-wainwright-4th-annual-nash-investor-conference-301139476.html
SOURCE Lipocine Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.